share_log

Mizuho Maintains Outperform on Cytokinetics, Raises Price Target to $103

Benzinga ·  Nov 21, 2024 08:10  · Ratings

Mizuho analyst Salim Syed maintains Cytokinetics (NASDAQ:CYTK) with a Outperform and raises the price target from $99 to $103.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment